GLP-1 Comparison: Semaglutide vs Tirzepatide vs Retatrutide
A high-level comparison of semaglutide, tirzepatide, and retatrutide focused on evidence maturity, receptor scope, and storage-confidence boundaries.
These three names are often compared as if they belong to one clean category, but they do not sit at the same evidence stage. That is the first fact a useful comparison has to keep visible.
Semaglutide is an approved GLP-1 product with mature labeled handling guidance. Tirzepatide is an approved dual agonist with its own label-backed storage and dosing structure. Retatrutide is still investigational, which means the clinical signal may be promising while the product-level handling certainty remains thinner than it is for approved, widely used formulations.
Why evidence maturity matters as much as mechanism
This comparison becomes useful only when it separates mechanism from confidence. Retatrutide may have a broader receptor profile, but that does not automatically place it on the same footing as a product with an approved label, established handling language, and post-approval real-world use. A broader mechanism and a stronger evidence package are not the same thing.
That distinction is especially important in storage and reconstitution conversations, where readers often borrow certainty from one molecule and apply it to another just because the names are discussed together. PeptideClock tries to stop that drift before it starts.
What stays the same across all three and what does not
The math does not care which name is on the vial. Concentration logic is the same across semaglutide, tirzepatide, and retatrutide, which is why the Peptide Calculator can support all three. But the calculator does not convert one evidence package into another. Storage language, titration context, and handling confidence still have to stay molecule-specific.
That is why a clean comparison has two layers. One layer is the shared concentration math. The other is the molecule-specific evidence tier. Confusing those layers is one of the main reasons GLP-1 comparison content becomes misleading so quickly.
Where to go deeper
If you want the pair-by-pair version rather than the overview, the molecule-specific compare pages are the better next step:
References & evidence
- Ozempic FDA label — source for semaglutide label-backed handling context.
- Mounjaro FDA label — source for tirzepatide label-backed handling context.
- STEP-1 trial — source for semaglutide trial context.
- SURMOUNT-1 trial — source for tirzepatide trial context.
- Retatrutide phase 2 trial — source for investigational retatrutide trial context.
